Premium
Cytokine expression in kidney transplant patients with acute allograft rejection
Author(s) -
Warner Roscoe L,
Barron Adam,
Cibrik Diane M,
Johnson Kent J
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.753.10
Subject(s) - medicine , chemokine , cytokine , cxcl1 , immunology , transplant rejection , peripheral blood mononuclear cell , kidney transplantation , immune system , interleukin 10 , kidney , biology , biochemistry , in vitro
With the development of a 108 protein antibody microarray, we have identified unique expression patterns in the serum of patients with biopsy‐proven acute cellular rejection versus healthy transplant patients. Levels of Gro‐α, IL‐1 RI, IL‐3, IL‐12, IP‐10, Fc‐γ RIIB, MCP‐3 and TGF‐α were significantly increased (p<0.05) in rejecting patients, relative to healthy transplants. Classically in the intense mononuclear inflammatory response of the acute allograft rejection there is an upregulation in the serum of pro‐inflammatory cytokines such as IL‐1, IL‐3, IL‐12, CXC chemokines IP‐10, MCP‐3 and Gro‐α, which are involved in leukocyte migration. Many of these cytokines are present in neutrophils and macrophages and are involved in cell activation and phagocytosis through the activation of NFκB. Conversely, we measured a significant decrease (p<0.05) in IL‐5, MCP‐1, MCP‐ 2, VEGF, MIP‐3α f z PDGF‐AB and TGF‐β2 in rejecting patients relative to the stable transplant patients. Frequently, in acute rejection a shift from TH1 to a TH2 type response is seen in patients with acute rejection as compared to stable transplants, which may explain the subsequent alteration in cytokine levels. These findings, while preliminary may eventually offer biomarkers of acute cellular rejection in patient serum, thus avoiding the need of a kidney biopsy. Work supported in part by NIH RO1 HL0709